Unfurling the Potential of Antiviral Agents Aimed for RNA Virus Ailment
Bibliographic record
Abstract
Globally, high mortality is brought on by RNA viruses, which are linked to chronic human disorders. Viruses dominate the WHO's current ranking of the top 10 global health hazards, especially RNA viruses. RNA viruses, like HIV, SARS-CoV-2, and influenza, which are among the most prevalent and frequently encountered RNA viruses, use RNA as their genetic material, making them prone to quick changes. They adapt rapidly, complicating the body's immune responses. HIV, a significant retrovirus, infiltrates the immune system, causing AIDS by compromising defenses against infections. SARS-CoV-2, which led to COVID-19, sparked a worldwide pandemic with respiratory symptoms, emphasizing the need for research and therapeutic innovations. The COVID-19 pandemic has demonstrated the insufficiency of available resources in effectively addressing emerging viral infections. Influenza, a seasonal RNA virus, triggers flu outbreaks, impacting public health. Research is crucial to understanding how these viruses interact with hosts, aiding the development of effective treatments and strengthening our ability to face new viral threats. The most effective defenses against viral illnesses are virus-specific vaccinations and antiviral drugs. The present review emphasizes the prevalence of the three most pathogenic and widespread RNA viruses, namely HIV, influenza, and SARS-CoV2, their pathophysiology, and the current treatment with FDA-approved drugs. It also incorporates novel analogs that are under clinical trials as there is an urgent need for innovative antiviral medications, and enormous global efforts are required to find secure and efficient cures for these viral infections.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.001 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.002 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.003 |
| Insufficient payload (model declined to judge) | 0.006 | 0.002 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".